keyword
MENU ▼
Read by QxMD icon Read
search

Second primary, lung cancer

keyword
https://www.readbyqxmd.com/read/27912764/sbrt-for-centrally-localized-nsclc-what-is-too-central
#1
J Roesch, C Panje, F Sterzing, F Mantel, U Nestle, N Andratschke, M Guckenberger
PURPOSE: Current guidelines recommend stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) in medically inoperable patients. There are excellent outcome and toxicity data for SBRT of peripheral lung tumors. However, the discussion on SBRT for centrally located tumors is controversial. This study evaluated current clinical practice regarding SBRT of centrally located lung tumors, to identify common fractionation schedules and commonly accepted contraindications for SBRT...
December 3, 2016: Radiation Oncology
https://www.readbyqxmd.com/read/27904449/tracheal-cancer-treatment-results-prognostic-factors-and-incidence-of-other-neoplasms
#2
Aleksandra Napieralska, Leszek Miszczyk, Sławomir Blamek
BACKGROUND: Tracheal cancers (TC) are rare and treatment results that are reported are typically not satisfactory. The purpose of this research was assessment of the results of treatment of TC patients, identification of potential additional surgery candidates, evaluation of prognostic factors, and assessment of the occurrence of other malignancies. PATIENTS AND METHODS: The Regional Cancer Database and the Hospital Database were searched for patients with tracheal neoplasms...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27902972/unravelling-site-specific-breast-cancer-metastasis-a-microrna-expression-profiling-study
#3
Willemijne A M E Schrijver, Paul J van Diest, Dutch Distant Breast Cancer Metastases Consortium, Cathy B Moelans
Distant metastasis is still the main cause of death from breast cancer. MicroRNAs (miRs) are important regulators of many physiological and pathological processes, including metastasis. Molecular breast cancer subtypes are known to show a site-specific pattern of metastases formation. In this study, we set out to determine the underlying molecular mechanisms of site-specific breast cancer metastasis by microRNA expression profiling.To identify a miR signature for metastatic breast carcinoma that could predict metastatic localization, we compared global miR expression in 23 primary breast cancer specimens with their corresponding multiple distant metastases to ovary (n=9), skin (n=12), lung (n=10), brain (n=4) and gastrointestinal tract (n=10) by miRCURY microRNA expression arrays...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27902597/whole-exome-sequencing-of-independent-lung-adenocarcinoma-lung-squamous-cell-carcinoma-and-malignant-peritoneal-mesothelioma-a-case-report
#4
Irene Vanni, Simona Coco, Silvia Bonfiglio, Davide Cittaro, Carlo Genova, Federica Biello, Marco Mora, Valeria Rossella, Maria Giovanna Dal Bello, Anna Truini, Barbara Banelli, Dejan Lazarevic, Angela Alama, Erika Rijavec, Giulia Barletta, Francesco Grossi
The presence of multiple primary tumors (MPT) in a single patient has been identified with an increasing frequency. A critical issue is to establish if the second tumor represents an independent primary cancer or a metastasis. Therefore, the assessment of MPT clonal origin might help understand the disease behavior and improve the management/prognosis of the patient.Herein, we report a 73-year-old male smoker who developed 2 primary lung cancers (adenocarcinoma and squamous cell carcinoma) and a malignant peritoneal mesothelioma (PM)...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27898657/serum-proteomic-test-in-advanced-non-squamous-non-small-cell-lung-cancer-treated-in-first-line-with-standard-chemotherapy
#5
F Grossi, E Rijavec, C Genova, G Barletta, F Biello, C Maggioni, G Burrafato, C Sini, M G Dal Bello, K Meyer, J Roder, H Roder, J Grigorieva
BACKGROUND: VeriStrat is a blood-based proteomic test with predictive and prognostic significance in second-line treatments for non-small cell lung cancer (NSCLC). This trial was designed to investigate the role of VeriStrat in first-line treatment of advanced NSCLC with standard chemotherapy. Here we present the results for 76 non-squamous patients treated with a combination of carboplatin or cisplatin with pemetrexed. METHODS: The test-assigned classifications of VeriStrat Good or VeriStrat Poor to samples collected at baseline...
November 29, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27891445/breast-cancer-with-synchronous-renal-cell-carcinoma-a-rare-presentation
#6
Ravi Arjunan, Durgesh Kumar, K V Veerendra Kumar, C S Premlatha
Primary cancer arising from multiple organs is a well known fact. Synchronous tumours have been most commonly associated with kidney cancer. Bladder, prostate, colorectal and lung cancer are the most common synchronous primaries with Renal Cell Carcinoma (RCC) identified till date. We found metachronous tumours of breast with RCC in literature search which included both metastatic tumours as well second primaries. Overall, 25 cases of metastatic breast tumours and eight cases of second primary in previously treated RCC have been reported in the literature...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27890346/the-uk-heartspare-study-stage-ii-multicentre-evaluation-of-a-voluntary-breath-hold-technique-in-patients-receiving-breast-radiotherapy
#7
F R Bartlett, E M Donovan, H A McNair, L A Corsini, R M Colgan, P M Evans, L Maynard, C Griffin, J S Haviland, J R Yarnold, A M Kirby
AIMS: To evaluate the feasibility and heart-sparing ability of the voluntary breath-hold (VBH) technique in a multicentre setting. MATERIALS AND METHODS: Patients were recruited from 10 UK centres. Following surgery for early left breast cancer, patients with any heart inside the 50% isodose from a standard free-breathing tangential field treatment plan underwent a second planning computed tomography (CT) scan using the VBH technique. A separate treatment plan was prepared on the VBH CT scan and used for treatment...
November 24, 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/27880766/sox2-and-pi3k-cooperate-to-induce-and-stabilize-a-squamous-committed-stem-cell-injury-state-during-lung-squamous-cell-carcinoma-pathogenesis
#8
Bo Ram Kim, Emily Van de Laar, Michael Cabanero, Shintaro Tarumi, Stefan Hasenoeder, Dennis Wang, Carl Virtanen, Takaya Suzuki, Bizhan Bandarchi, Shingo Sakashita, Nhu An Pham, Sharon Lee, Shaf Keshavjee, Thomas K Waddell, Ming-Sound Tsao, Nadeem Moghal
Although cancers are considered stem cell diseases, mechanisms involving stem cell alterations are poorly understood. Squamous cell carcinoma (SQCC) is the second most common lung cancer, and its pathogenesis appears to hinge on changes in the stem cell behavior of basal cells in the bronchial airways. Basal cells are normally quiescent and differentiate into mucociliary epithelia. Smoking triggers a hyperproliferative response resulting in progressive premalignant epithelial changes ranging from squamous metaplasia to dysplasia...
November 2016: PLoS Biology
https://www.readbyqxmd.com/read/27863726/-met-receptor-inhibition-hope-against-resistance-to-targeted-therapies
#9
REVIEW
Audrey Hochart, Pierre Leblond, Xuefen Le Bourhis, Samuel Meignan, David Tulasne
Overcoming the drug resistance remains a crucial issue in cancer treatment. For refractory patients, the use of MET receptor tyrosine kinase inhibitors seems to be hopeful. Indeed, important mechanisms underlying drug resistance argue for association of MET inhibitors with targeted therapies, both on first-line to prevent a primary resistance and on the second line to overcoming acquired resistance. Indeed, met gene amplification is the second most common alteration involved in acquired resistance to anti-epidermal growth factor receptor (EGFR) therapies in non-small cells lung cancer (NSCLC)...
November 15, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27859136/kras-driven-expression-signature-has-prognostic-power-superior-to-mutation-status-in-non-small-cell-lung-cancer
#10
Ádám Nagy, Lőrinc Sándor Pongor, András Szabó, Mariacarmela Santarpia, Balázs Győrffy
KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS mutation status will have the most prominent effect and could be used as a prognostic signature in lung cancer. We divided NSCLC patients with mutation and RNA-seq data into KRAS mutated and wild type groups. Mann-Whitney test was used to identify genes showing altered expression between these cohorts...
November 8, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27843623/phase-ii-study-of-erlotinib-plus-tivantinib-arq-197-in-patients-with-locally-advanced-or-metastatic-egfr-mutation-positive-non-small-cell-lung-cancer-just-after-progression-on-egfr-tki-gefitinib-or-erlotinib
#11
Koichi Azuma, Tomonori Hirashima, Nobuyuki Yamamoto, Isamu Okamoto, Toshiaki Takahashi, Makoto Nishio, Taizo Hirata, Kaoru Kubota, Kazuo Kasahara, Toyoaki Hida, Hiroshige Yoshioka, Kaoru Nakanishi, Shiro Akinaga, Kazuto Nishio, Tetsuya Mitsudomi, Kazuhiko Nakagawa
BACKGROUND: Patients with epidermal growth factor receptor (EGFR) activation mutation-positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but eventually become resistant in most cases. The hepatocyte growth factor/c-Met (HGF/c-Met) pathway is reported as a poor prognostic factor in various cancers. As c-Met is involved in EGFR-TKI resistance, a c-Met inhibitor and EGFR-TKI combination may reverse the resistance. This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs...
2016: ESMO Open
https://www.readbyqxmd.com/read/27836618/a-new-classification-method-for-maldi-imaging-mass-spectrometry-data-acquired-on-formalin-fixed-paraffin-embedded-tissue-samples
#12
Tobias Boskamp, Delf Lachmund, Janina Oetjen, Yovany Cordero Hernandez, Dennis Trede, Peter Maass, Rita Casadonte, Jörg Kriegsmann, Arne Warth, Hendrik Dienemann, Wilko Weichert, Mark Kriegsmann
Matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) shows a high potential for applications in histopathological diagnosis, and in particular for supporting tumor typing and subtyping. The development of such applications requires the extraction of spectral fingerprints that are relevant for the given tissue and the identification of biomarkers associated with these spectral patterns. We propose a novel data analysis method based on the extraction of characteristic spectral patterns (CSPs) that allow automated generation of classification models for spectral data...
November 9, 2016: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/27825638/erlotinib-cabozantinib-or-erlotinib-plus-cabozantinib-as-second-line-or-third-line-treatment-of-patients-with-egfr-wild-type-advanced-non-small-cell-lung-cancer-ecog-acrin-1512-a-randomised-controlled-open-label-multicentre-phase-2-trial
#13
Joel W Neal, Suzanne E Dahlberg, Heather A Wakelee, Seena C Aisner, Michaela Bowden, Ying Huang, David P Carbone, Gregory J Gerstner, Rachel E Lerner, Jerome L Rubin, Taofeek K Owonikoko, Philip J Stella, Preston D Steen, Ahmed Ali Khalid, Suresh S Ramalingam
BACKGROUND: Erlotinib is approved for the treatment of all patients with advanced non-small-cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. Cabozantinib, a small molecule tyrosine kinase inhibitor, targets MET, VEGFR, RET, ROS1, and AXL, which are implicated in lung cancer tumorigenesis. We compared the efficacy of cabozantinib alone or in combination with erlotinib versus erlotinib alone in patients with EGFR wild-type NSCLC. METHODS: This three group, randomised, controlled, open-label, multicentre, phase 2 trial was done in 37 academic and community oncology practices in the USA...
November 4, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27823977/a-randomized-phase-ii-study-of-gefitinib-alone-versus-nimotuzumab-plus-gefitinib-after-platinum-based-chemotherapy-in-advanced-non-small-cell-lung-cancer-kcsg-lu12-01
#14
Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, Myung-Ju Ahn, Dong-Wan Kim, Inkyung Jung, Ki Hyeong Lee, Joo-Hang Kim, Dae Ho Lee, Sang-We Kim, Byoung Chul Cho
We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. An open label, randomized, phase II trial was conducted at 6 centers; 160 patients were randomized (1:1) to either gefitinib alone or nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily) until disease progression or intolerable toxicity...
November 3, 2016: Oncotarget
https://www.readbyqxmd.com/read/27793399/does-repeated-lung-resection-provide-long-term-survival-for-recurrent-pulmonary-metastases-of-colorectal-cancer-%C3%A2-results-of-a-retrospective-japanese%C3%A2-multicenter-study
#15
Tomoyuki Hishida, Masahiro Tsuboi, Takehiro Okumura, Narikazu Boku, Yasuhisa Ohde, Yukinori Sakao, Katsuo Yoshiya, Ichinosuke Hyodo, Keita Mori, Haruhiko Kondo
BACKGROUND: The purpose of this study was to clarify the long-term survival outcomes after repeated lung resection (RLR) of pulmonary metastases from colorectal cancer (PM-CRC) using data from a Japanese nationwide investigation. METHODS: Among 898 patients who underwent R0 resection of PM-CRC at 46 Japanese institutions between 2004 and 2008, we analyzed the data of 216 patients who experienced recurrence limited to the lung after initial resection of PM-CRC. Overall survival (OS) after RLR was analyzed, and prognostic factors were explored using a multivariate Cox analysis...
October 25, 2016: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/27766477/risk-of-second-primary-malignancies-in-lung-cancer-survivors-the-influence-of-different-treatments
#16
Vincent Yi-Fong Su, Chia-Jen Liu, Yuh-Min Chen, Teh-Ying Chou, Tzeng-Ji Chen, Sang-Hue Yen, Tzeon-Jye Chiou, Jin-Hwang Liu, Yu-Wen Hu
BACKGROUND: Currently, no large study addressing the relationship between lung cancer patients with different therapies and second primary malignancies (SPMs) is available. METHODS: Using the Taiwan National Health Insurance Research Database, we conducted a population-based cohort study. Patients with newly diagnosed lung cancer between 1997 and 2005 were enrolled and followed up until Dec. 31, 2011. The endpoint of the study was SPM occurrence. Standardized incidence ratios (SIRs) of cancers were calculated to compare the cancer incidence of the study cohort to that of the general population...
October 20, 2016: Targeted Oncology
https://www.readbyqxmd.com/read/27763916/hemodynamic-instability-following-airway-spray-cryotherapy
#17
Alessia Pedoto, Dawn P Desiderio, David Amar, Robert J Downey
BACKGROUND: Spray cryotherapy (SCT) of airway lesions is used to effectively palliate respiratory symptoms related to airway obstruction, but significant intraoperative hemodynamic complications have been noted. We reviewed the experience at a single institution using SCT for the treatment of obstructive airway tumors. METHODS: A retrospective review of a single institution experience with intraoperative and postoperative hemodynamic complications associated with SCT was performed...
November 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/27756320/a-case-of-peritoneal-metastasis-during-treatment-for-hypopharyngeal-squamous-cell-carcinoma
#18
Takahiro Wakasaki, Hirofumi Omori, Shintaro Sueyoshi, Fumihide Rikimaru, Satoshi Toh, Kenichi Taguchi, Yuichiro Higaki, Masaru Morita, Muneyuki Masuda
BACKGROUND: Advanced head and neck squamous cell carcinomas frequently develop distant metastases to limited organs, including the lungs, bone, mediastinal lymph nodes, brain, and liver. Peritoneal carcinomatosis as an initial distant metastasis from hypopharyngeal squamous cell carcinoma is quite rare. CASE PRESENTATION: A 75-year-old man diagnosed with hypopharyngeal squamous cell carcinoma and his clinical stage was determined as T2N2cM0. Notably, the right retropharyngeal lymph node surrounded more than half of the right internal carotid artery...
October 18, 2016: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27733477/clinically-viable-gene-expression-assays-with-potential-for-predicting-benefit-from-mek-inhibitors
#19
Roz G Brant, Alan Sharpe, Tom Liptrot, Jonathan Dry, Elizabeth A Harrington, J Carl Barrett, Nicky Whalley, Chris Womack, Paul D Smith, Darren Hodgson
PURPOSE: To develop a clinically viable gene expression assay to measure RAS/RAF/MEK/ERK (RAS-ERK) pathway output suitable for hypothesis testing in non-small cell lung cancer (NSCLC) clinical studies. EXPERIMENTAL DESIGN: A published MEK-functional-activation signature (MEK signature) that measures RAS-ERK functional output was optimized for NSCLC in silico. NanoString assays were developed for the NSCLC optimized MEK signature and the 147-gene RAS signature. First, platform transfer from Affymetrix to NanoString, and signature modulation following treatment with KRAS siRNA and MEK inhibitor, were investigated in cell lines...
October 12, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27676550/p2-14-lung-cancer-as-second-primary-cancer%C3%A2-in-two-patients-in-a-reference%C3%A2-hospital-in-latin-america-%C3%A2-a%C3%A2-case-report-track-pathology
#20
Karen Monroy Orozco, Liliana Fernandez Trujillo, Luz F Sua
No abstract text is available yet for this article.
October 2016: Journal of Thoracic Oncology
keyword
keyword
89877
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"